Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance

View ORCID ProfileMohd A Karim, Jarrod Shilts, View ORCID ProfileJeremy Schwartzentruber, James Hayhurst, View ORCID ProfileAnnalisa Buniello, View ORCID ProfileElmutaz Shaikho Elhaj Mohammed, Jie Zheng, View ORCID ProfileMichael V Holmes, David Ochoa, Miguel Carmona, Joseph Maranville, Tom R. Gaunt, View ORCID ProfileValur Emilsson, Vilmundur Gudnason, Ellen M. McDonagh, Gavin J. Wright, Maya Ghoussaini, Ian Dunham
doi: https://doi.org/10.1101/2021.03.15.21253625
Mohd A Karim
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohd A Karim
  • For correspondence: mk31@sanger.ac.uk mg29@sanger.ac.uk dunham@ebi.ac.uk
Jarrod Shilts
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Schwartzentruber
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeremy Schwartzentruber
James Hayhurst
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annalisa Buniello
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annalisa Buniello
Elmutaz Shaikho Elhaj Mohammed
4Bristol-Myers Squibb, Cambridge, MA 02142, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elmutaz Shaikho Elhaj Mohammed
Jie Zheng
5MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol. BS8 2BN. UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael V Holmes
6Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK
7Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael V Holmes
David Ochoa
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Carmona
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Maranville
4Bristol-Myers Squibb, Cambridge, MA 02142, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom R. Gaunt
5MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol. BS8 2BN. UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valur Emilsson
8Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
9Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Valur Emilsson
Vilmundur Gudnason
8Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
9Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen M. McDonagh
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavin J. Wright
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
10Department of Biology, York Biomedical Research Institute, Hull York Medical School, University of York, York, North Yorkshire YO10 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya Ghoussaini
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mk31@sanger.ac.uk mg29@sanger.ac.uk dunham@ebi.ac.uk
Ian Dunham
1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
2Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
3European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mk31@sanger.ac.uk mg29@sanger.ac.uk dunham@ebi.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The virus SARS-CoV-2 can exploit biological vulnerabilities in susceptible hosts that predispose to development of severe COVID-19. Previous reports have identified several host proteins related to the interferon response (e.g. OAS1), interleukin-6 signalling (IL-6R), and the coagulation cascade (linked via ABO) that were associated with risk of COVID-19. In the present study, we performed proteome-wide genetic colocalisation tests leveraging publicly available protein and COVID-19 datasets, to identify additional proteins that may contribute to COVID-19 risk. Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble FAS (colocalisation probability > 0.9, p = 1 × 10−4), implicating FAS-mediated apoptosis as a potential target for COVID-19 risk. We also undertook polygenic (pan) and cis-Mendelian randomisation analyses that showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal was associated with plasma concentrations of several proteins, with the strongest association observed with CD209 in several proteomic datasets. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19.

Competing Interest Statement

JM and ESEM are full-time employees of Bristol-Myers Squibb.

Funding Statement

MAK, JSc, JH, AB, DO, MC, EMM, MG, ID were funded by Open Targets. J.Z. and T.R.G were funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4). JSh and GJW were funded by the Wellcome Trust Grant 206194.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Open Targets

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† Joint Senior Authors

Data Availability

Summary data used for genetic analyses are publicly available (Sun et al can be downloaded from GWAS catalog https://www.ebi.ac.uk/gwas/downloads/summary-statistics and COVID-19 HGI summary statistics can be downloaded from their website https://www.covid19hg.org/results/). Data generated from our study are provided in the supplementary tables (pan-MR and cis-MR association results filtered at p < 0.05 and no filters applied to colocalisation results).

https://www.ebi.ac.uk/gwas/downloads/summary-statistics

https://www.covid19hg.org/results/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 17, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
Mohd A Karim, Jarrod Shilts, Jeremy Schwartzentruber, James Hayhurst, Annalisa Buniello, Elmutaz Shaikho Elhaj Mohammed, Jie Zheng, Michael V Holmes, David Ochoa, Miguel Carmona, Joseph Maranville, Tom R. Gaunt, Valur Emilsson, Vilmundur Gudnason, Ellen M. McDonagh, Gavin J. Wright, Maya Ghoussaini, Ian Dunham
medRxiv 2021.03.15.21253625; doi: https://doi.org/10.1101/2021.03.15.21253625
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
Mohd A Karim, Jarrod Shilts, Jeremy Schwartzentruber, James Hayhurst, Annalisa Buniello, Elmutaz Shaikho Elhaj Mohammed, Jie Zheng, Michael V Holmes, David Ochoa, Miguel Carmona, Joseph Maranville, Tom R. Gaunt, Valur Emilsson, Vilmundur Gudnason, Ellen M. McDonagh, Gavin J. Wright, Maya Ghoussaini, Ian Dunham
medRxiv 2021.03.15.21253625; doi: https://doi.org/10.1101/2021.03.15.21253625

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)